Amedeo Smart

Free Medical Literature Service

 

Amedeo

Biliary Tract Diseases
  Free Subscription

Articles published in
J Hepatol
    July 2026
  1. TEN HAAFT BHEA, Bonomi AM, Groot Koerkamp B, Olthof P, et al
    An ABC approach for preoperative staging in perihilar cholangiocarcinoma An international multicenter cohort study.
    J Hepatol. 2026 Jul 24:S0168-8278(26)02740-6. doi: 10.1016/j.jhep.2026.
    >> Share

  2. ASSIS DN
    Delphi Consensus in Primary Biliary Cholangitis: Collective Introspection to Set a Forward Path.
    J Hepatol. 2026 Jul 17:S0168-8278(26)02720-0. doi: 10.1016/j.jhep.2026.
    >> Share

  3. XU Q, Zhou S, Zhang C, Zhou Y, et al
    Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial.
    J Hepatol. 2026 Jul 6:S0168-8278(26)02682-6. doi: 10.1016/j.jhep.2026.
    >> Share

  4. OH DY, Ikeda M, Macarulla T, He AR, et al
    Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.
    J Hepatol. 2026 Jul 6:S0168-8278(26)02658-9. doi: 10.1016/j.jhep.2026.
    >> Share

    June 2026
  5. ROUSIAN M, Alessandris R, Schleimer L, Kalvin H, et al
    Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials.
    J Hepatol. 2026 Jun 22:S0168-8278(26)02655-3. doi: 10.1016/j.jhep.2026.
    >> Share

  6. KALAL CR, Gupta P
    Rifaximin and the DCA-serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?
    J Hepatol. 2026 Jun 20:S0168-8278(26)02650-4. doi: 10.1016/j.jhep.2026.
    >> Share

  7. LAMARCA A, Harding JJ, Oh DY
    Systemic therapy of biliary tract cancer: The road to personalised strategies.
    J Hepatol. 2026 Jun 8:S0168-8278(26)00128-5. doi: 10.1016/j.jhep.2026.
    >> Share

    May 2026
  8. CHEW V
    Neoadjuvant GOLP for high-risk resectable intrahepatic cholangiocarcinoma: Shifting the treatment paradigm?
    J Hepatol. 2026 May 29:S0168-8278(26)00286-2. doi: 10.1016/j.jhep.2026.
    >> Share

  9. TRAMPERT DC
    On the use of UDCA beyond cholestatic liver disease: How bile acid-driven intestinal GLP-1 signalling keeps the joints healthy.
    J Hepatol. 2026 May 28:S0168-8278(26)00283-7. doi: 10.1016/j.jhep.2026.
    >> Share


  10. EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis.
    J Hepatol. 2026 May 27:S0168-8278(26)00193-5. doi: 10.1016/j.jhep.2026.
    >> Share

  11. EATON JE, Erickson BJ, Venkatesh SK
    A call for action: The need to quantify the "-itis" in primary sclerosing cholangitis.
    J Hepatol. 2026 May 26:S0168-8278(26)00290-4. doi: 10.1016/j.jhep.2026.
    >> Share

  12. SCHIRMACHER P, Longerich T
    Histopathology matters for imaging and clinical correlations in Primary Sclerosing Cholangitis.
    J Hepatol. 2026 May 26:S0168-8278(26)00289-8. doi: 10.1016/j.jhep.2026.
    >> Share

  13. GENOVESI V, Salani F, Rimini M, Masi G, et al
    Response to: "Establish a streamlined molecular profiling workflow for the clinical management of advanced cholangiocarcinoma".
    J Hepatol. 2026 May 21:S0168-8278(26)00285-0. doi: 10.1016/j.jhep.2026.
    >> Share

    April 2026
  14. SABOROWSKI A, Vogel A
    Global biliary tract cancer genomics: from geographic patterns toward biological subtypes.
    J Hepatol. 2026 Apr 28:S0168-8278(26)00225-4. doi: 10.1016/j.jhep.2026.
    >> Share

  15. SUN Q, Ramos SG, Schwabe RF
    Beyond proliferation: YAP shapes the tumor identity and immune landscape of intrahepatic cholangiocarcinoma.
    J Hepatol. 2026 Apr 18:S0168-8278(26)00209-6. doi: 10.1016/j.jhep.2026.
    >> Share

  16. SCHRAMM C, Potter-Lang S, Halilbasic E, Ba-Ssalamah A, et al
    Primary sclerosing cholangitis: time to rethink imaging criteria for early disease detection.
    J Hepatol. 2026 Apr 18:S0168-8278(26)00212-6. doi: 10.1016/j.jhep.2026.
    >> Share

  17. BRAADLAND PR, Ali AH, Puchas P, Juran BD, et al
    Vitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis.
    J Hepatol. 2026 Apr 17:S0168-8278(26)00203-5. doi: 10.1016/j.jhep.2026.
    >> Share

  18. RAMACHANDRAN P
    Assembling a new model to interrogate human liver biliary diseases.
    J Hepatol. 2026 Apr 15:S0168-8278(26)00130-3. doi: 10.1016/j.jhep.2026.
    >> Share

    March 2026
  19. ZHU Y, Wu JA, Zhang D, Chowdhury S, et al
    Global patterns of mutational profiles in biliary tract cancer.
    J Hepatol. 2026 Mar 28:S0168-8278(26)00157-1. doi: 10.1016/j.jhep.2026.
    >> Share

  20. MANCO R, Moliterni C, Neirynck G, Claus R, et al
    Liver Sinusoidal Endothelial Cells and Laminin dictate cholangiocytes' fate in chronic liver disease.
    J Hepatol. 2026 Mar 27:S0168-8278(26)00148-0. doi: 10.1016/j.jhep.2026.
    >> Share

  21. LI S, Tong G, Xue M, Shen L, et al
    Activated hepatic stellate cells maintain liver bile acid homeostasis through paracrine FGF10/FGFR2 signaling.
    J Hepatol. 2026 Mar 26:S0168-8278(26)00149-2. doi: 10.1016/j.jhep.2026.
    >> Share

  22. PAPADAKOS SP, Argyrou A, Papatheodoridis GV
    Beyond alkaline phopshatase: can anti-integrin alphavbeta6 autoantibodies serve as biomarkers in primary sclerosing cholangitis trials?
    J Hepatol. 2026 Mar 17:S0168-8278(26)00140-6. doi: 10.1016/j.jhep.2026.
    >> Share

  23. ZHAO J, Yang L, Qin Y, Zhang Y, et al
    Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression: Roles of AKT and YAP during iCCA.
    J Hepatol. 2026 Mar 4:S0168-8278(26)00119-4. doi: 10.1016/j.jhep.2026.
    >> Share

    February 2026
  24. JULIEBO AT, Folseraas T, Karlsen TH, Boberg KM, et al
    Differences in Immunosuppressive Strategies for Primary Sclerosing Cholangitis After Liver Transplantation.
    J Hepatol. 2026 Feb 19:S0168-8278(26)00073-5. doi: 10.1016/j.jhep.2026.
    >> Share

  25. CHEN Y, Li J, Lan C
    Establish a streamlined molecular profiling workflow for the clinical management of advanced cholangiocarcinoma.
    J Hepatol. 2026 Feb 15:S0168-8278(26)00076-0. doi: 10.1016/j.jhep.2026.
    >> Share

    January 2026
  26. XU K, Dong X, Qu H, Hu J, et al
    AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC: Effect of the BA/Butyrate/CXCL14 axis in HCC.
    J Hepatol. 2026 Jan 21:S0168-8278(26)00016-4. doi: 10.1016/j.jhep.2025.
    >> Share

    December 2025
  27. GENOVESI V, Salani F, Rimini M, Rizzato MD, et al
    Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA).
    J Hepatol. 2025 Dec 26:S0168-8278(25)02735-7. doi: 10.1016/j.jhep.2025.
    >> Share

  28. TRAMPERT DC
    Viral infection as a trigger for primary sclerosing cholangitis in genetically susceptible individuals.
    J Hepatol. 2025 Dec 11:S0168-8278(25)02632-7. doi: 10.1016/j.jhep.2025.
    >> Share

  29. KEITEL V, Kreissl MC, Goetze T, Droge C, et al
    CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement.
    J Hepatol. 2025 Dec 8:S0168-8278(25)02711-4. doi: 10.1016/j.jhep.2025.
    >> Share

    November 2025
  30. YOON J, Lee CK, Kim JW, Kang B, et al
    Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.
    J Hepatol. 2025 Nov 24:S0168-8278(25)02626-1. doi: 10.1016/j.jhep.2025.
    >> Share

  31. RODRIGUES PM, Banales JM
    RePARylating biliary tumours to improve the efficacy of chemoimmunotherapy.
    J Hepatol. 2025 Nov 7:S0168-8278(25)02611-X. doi: 10.1016/j.jhep.2025.
    >> Share

  32. FRANCIS H, Glaser S, Ueno Y, Lesage G, et al
    Corrigendum to 'cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway' (J Hepatol 41 [2004] 528-537).
    J Hepatol. 2025 Nov 7:S0168-8278(25)02563-2. doi: 10.1016/j.jhep.2025.
    >> Share

  33. ASSIS DN, Hov JR
    Phase 2 Clinical Trials in Primary Sclerosing Cholangitis: Making the Most of Every Opportunity?
    J Hepatol. 2025 Nov 4:S0168-8278(25)02605-4. doi: 10.1016/j.jhep.2025.
    >> Share

    October 2025
  34. MERZ V
    Two lenses, same picture: interpreting nal-IRI in biliary tract cancer.
    J Hepatol. 2025 Oct 17:S0168-8278(25)02560-7. doi: 10.1016/j.jhep.2025.
    >> Share

  35. WONG YJ, Lam L, Soret PA, Lemoinne S, et al
    Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.
    J Hepatol. 2025 Oct 3:S0168-8278(25)02519-X. doi: 10.1016/j.jhep.2025.
    >> Share

  36. CUI T, Sun L, Guo X, Cheng C, et al
    Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response.
    J Hepatol. 2025;83:946-958.
    >> Share

    September 2025
  37. GALANAKIS V, Gribben C, Munteanu A, Cagna M, et al
    Transcriptomic and epigenetic mechanisms controlling cholangiocytes transdifferentiation into hepatocytes.
    J Hepatol. 2025 Sep 29:S0168-8278(25)02516-4. doi: 10.1016/j.jhep.2025.
    >> Share

  38. YU M, Xie P, Yu Q, Zhao Y, et al
    PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy.
    J Hepatol. 2025 Sep 26:S0168-8278(25)02500-0. doi: 10.1016/j.jhep.2025.
    >> Share

  39. HIRSCHFIELD GM, Kowdley KV, Trivedi PJ, Eksteen B, et al
    Phase II INTEGRIS-PSC trial of bexotegrast, an alphavbeta6/alphavbeta1 integrin inhibitor, in primary sclerosing cholangitis.
    J Hepatol. 2025 Sep 26:S0168-8278(25)02498-5. doi: 10.1016/j.jhep.2025.
    >> Share

  40. MARONI L, Marzioni M
    Reply to "Time to standardize preoperative EUS for lymph node staging in resectable extrahepatic cholangiocarcinoma".
    J Hepatol. 2025 Sep 18:S0168-8278(25)02481-X. doi: 10.1016/j.jhep.2025.
    >> Share

  41. SUN D, Wang D, Jia L, Wang P, et al
    S1P/S1PR4 Promotes the Differentiation of CD8(+) tissue-resident memory T Cells Aggravating Bile Duct Injury in Biliary Atresia.
    J Hepatol. 2025 Sep 5:S0168-8278(25)02472-9. doi: 10.1016/j.jhep.2025.
    >> Share

    August 2025
  42. DIXON ED, Claudel T, Nardo AD, Riva A, et al
    Erratum to 'Inhibition of ATGL alleviates MASH via impaired PPARa signalling that favours hydrophilic bile acid composition in mice' [J Hepatol 82 (2025) 658-675].
    J Hepatol. 2025 Aug 30:S0168-8278(25)02438-9. doi: 10.1016/j.jhep.2025.
    >> Share

  43. SCHWINGE D, Schramm C
    Tregs going acid - how cholestasis impairs regulatory T cell function.
    J Hepatol. 2025 Aug 29:S0168-8278(25)02441-9. doi: 10.1016/j.jhep.2025.
    >> Share

  44. CHAN SL, Lamarca A, Hsu C, Moreno V, et al
    New targets and new drugs for hepatobiliary cancers.
    J Hepatol. 2025 Aug 25:S0168-8278(25)02455-9. doi: 10.1016/j.jhep.2025.
    >> Share

  45. DEL ZOMPO F, Crouchet E, Ostyn T, Nehme Z, et al
    Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02440-7. doi: 10.1016/j.jhep.2025.
    >> Share

  46. TRAMPERT DC
    From parts to portal: Recapitulating hepatobiliary microarchitecture using multicellular organoids.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02346-3. doi: 10.1016/j.jhep.2025.
    >> Share

  47. JEONG H, Oh JH, Ahn HS, Ryoo BY, et al
    Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Aug 11:S0168-8278(25)02402-X. doi: 10.1016/j.jhep.2025.
    >> Share

  48. ZHANG R, Su L, Fu M, Wang Z, et al
    Corrigendum to: 'CD177(+) cells produce neutrophil extracellular traps that promote biliary atresia' (J Hepatol [2022] 77:1299-1310).
    J Hepatol. 2025 Aug 4:S0168-8278(25)02281-0. doi: 10.1016/j.jhep.2025.
    >> Share

  49. HE J, Zhang M, Shi Y, Ji Z, et al
    Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02382-7. doi: 10.1016/j.jhep.2025.
    >> Share

    July 2025
  50. PU X, Liu Y, Lyu Z, Zhou Y, et al
    B cells drive CCR5(+)CD4(+) tissue-resident memory T cell cytotoxicity via IL-15Ralpha-IL-15 signaling in primary biliary cholangitis.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02340-2. doi: 10.1016/j.jhep.2025.
    >> Share

  51. LIU H, Wang J, Yao Y, Xia T, et al
    Restoration of N-glycosylation via leucine-activated leucyl-tRNA synthetase 1 overcomes chemoresistance in intrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02344-X. doi: 10.1016/j.jhep.2025.
    >> Share

  52. DE JONG DM, Lammers WJ, van Driel LMJW
    Time to standardize preoperative EUS for lymph node staging in resectable extrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Jul 9:S0168-8278(25)02332-3. doi: 10.1016/j.jhep.2025.
    >> Share

  53. VOGEL A, Saborowski A
    Chasing shadows: navigating surrogate endpoints in biliary tract cancer.
    J Hepatol. 2025 Jul 8:S0168-8278(25)02325-6. doi: 10.1016/j.jhep.2025.
    >> Share

    June 2025
  54. BEUERS U, Banales JM, Karpen S, Keitel V, et al
    History and prospects of bile acid therapies.
    J Hepatol. 2025 Jun 20:S0168-8278(25)02277-9. doi: 10.1016/j.jhep.2025.
    >> Share

  55. KUDIRA R, Yang ZF, Osuji I, Damen MSMA, et al
    Bile acids engage the SIPR-STAT3 signaling axis to modulate regulatory T cell responses in fibrosing cholangiopathies.
    J Hepatol. 2025 Jun 20:S0168-8278(25)02271-8. doi: 10.1016/j.jhep.2025.
    >> Share

  56. RODRIGUEZ N, Katzenstein C, O'Kula S, Kushner T, et al
    Use of maralixibat in severe and recurrent intrahepatic cholestasis of pregnancy with concurrent benign recurrent intrahepatic cholestasis (BRIC).
    J Hepatol. 2025 Jun 18:S0168-8278(25)02249-4. doi: 10.1016/j.jhep.2025.
    >> Share

  57. TRAMPERT DC
    Bile acid species as hepatic T lymphocyte response modulators - when bile acids interfere with tumor growth.
    J Hepatol. 2025 Jun 5:S0168-8278(25)00249-1. doi: 10.1016/j.jhep.2025.
    >> Share

  58. CASTET F, Fabregat-Franco C, Bridgewater J, Kim JW, et al
    Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer.
    J Hepatol. 2025 Jun 3:S0168-8278(25)02251-2. doi: 10.1016/j.jhep.2025.
    >> Share

    May 2025
  59. GHALLAB A, Mandorfer M, Stirnimann G, Geyer J, et al
    Enteronephrohepatic Circulation of Bile Acids and Therapeutic Potential of Systemic Bile Acid Transporter Inhibitors.
    J Hepatol. 2025 May 23:S0168-8278(25)02207-X. doi: 10.1016/j.jhep.2025.
    >> Share

  60. OH DY, He AR, Qin S, Chen LT, et al
    Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
    J Hepatol. 2025 May 15:S0168-8278(25)02201-9. doi: 10.1016/j.jhep.2025.
    >> Share

  61. NIU M, Ding WX
    Overcoming drug resistance by harnessing mitochondrial divisome for treating cholangiocarcinoma.
    J Hepatol. 2025 May 9:S0168-8278(25)02197-X. doi: 10.1016/j.jhep.2025.
    >> Share

  62. LEVY C, Abouda GF, Bilir BM, Bonder A, et al
    Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
    J Hepatol. 2025 May 8:S0168-8278(25)00252-1. doi: 10.1016/j.jhep.2025.
    >> Share

  63. OLAIZOLA I, Odriozola-Gimeno M, Olaizola P, Caballero-Camino FJ, et al
    New platinum derivatives selectively cause double-strand DNA breaks and death in naive and cisplatin-resistant cholangiocarcinomas.
    J Hepatol. 2025 May 3:S0168-8278(25)00293-4. doi: 10.1016/j.jhep.2025.
    >> Share

    April 2025

  64. EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Apr 30:S0168-8278(25)00162-X. doi: 10.1016/j.jhep.2025.
    >> Share

  65. LV GY, Mu WT, Cao YN, Sun XD, et al
    Cisplatin-induced Disruption of Mitochondrial Divisome Leads to Enhanced Cisplatin Resistance in Cholangiocarcinoma.
    J Hepatol. 2025 Apr 4:S0168-8278(25)00219-3. doi: 10.1016/j.jhep.2025.
    >> Share

    March 2025
  66. YOO C, Ueno M, Klumpen HJ, Kelley RK, et al
    Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.
    J Hepatol. 2025 Mar 26:S0168-8278(25)00207-7. doi: 10.1016/j.jhep.2025.
    >> Share

  67. YOO C, Saborowski A, Hyung J, Wenzel P, et al
    Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials.
    J Hepatol. 2025 Mar 25:S0168-8278(25)00169-2. doi: 10.1016/j.jhep.2025.
    >> Share

  68. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
    Erratum to: 'Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis' [J Hepatol (2024) 80:268-281].
    J Hepatol. 2025 Mar 15:S0168-8278(25)00140-0. doi: 10.1016/j.jhep.2025.
    >> Share

  69. KOLEV M, Moller B, Berzigotti A, Semmo N, et al
    Upadacitinib for refractory Primary Biliary Cholangitis.
    J Hepatol. 2025 Mar 12:S0168-8278(25)00159-X. doi: 10.1016/j.jhep.2025.
    >> Share

    February 2025
  70. TRAMPERT DC
    B cell-depleting anti-CD19 monoclonal antibody holds promise for treating IgG4-related cholangitis.
    J Hepatol. 2025 Feb 27:S0168-8278(25)00070-4. doi: 10.1016/j.jhep.2025.
    >> Share

  71. KNOX JJ, McNamara MG, Bazin IS, Oh DY, et al
    A phase III randomised study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.
    J Hepatol. 2025 Feb 18:S0168-8278(25)00085-6. doi: 10.1016/j.jhep.2025.
    >> Share

  72. HWANG S, Woo S, Kim C, Chon HJ, et al
    Reply to: Correspondence on 'Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer'.
    J Hepatol. 2025 Feb 12:S0168-8278(25)00082-0. doi: 10.1016/j.jhep.2025.
    >> Share

  73. YOO C
    Response to Zhang et al.: Evaluating Clinical Utility of CT DNA Monitoring for Recurrence Prediction in Resected Extrahepatic Cholangiocarcinoma.
    J Hepatol. 2025 Feb 12:S0168-8278(25)00081-9. doi: 10.1016/j.jhep.2025.
    >> Share

  74. XUE X, Liu R, Cai Y, Gong L, et al
    Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m(6)A-regulated expression of a novel anti-fibrotic target ETV4.
    J Hepatol. 2025 Feb 4:S0168-8278(25)00055-8. doi: 10.1016/j.jhep.2025.
    >> Share

    January 2025
  75. NYHOLM I, Hukkinen M, Lohi J, Sjoblom N, et al
    Accumulation of altered serum bile acids predicts liver injury after portoenterostomy in biliary atresia.
    J Hepatol. 2025 Jan 29:S0168-8278(25)00062-5. doi: 10.1016/j.jhep.2025.
    >> Share

  76. CHUNG T, Oh S, Won J, Park J, et al
    Genomic and transcriptomic signatures of sequential carcinogenesis from papillary neoplasm to biliary tract cancer.
    J Hepatol. 2025 Jan 18:S0168-8278(25)00013-3. doi: 10.1016/j.jhep.2025.
    >> Share

    December 2024
  77. ZHANG Y, Wang K, Song Z
    Evaluating Clinical Utility of CT DNA Monitoring for Recurrence Prediction in Resected Extrahepatic Cholangiocarcinoma.
    J Hepatol. 2024 Dec 9:S0168-8278(24)02742-9. doi: 10.1016/j.jhep.2024.
    >> Share

    November 2024
  78. WANG K, Chen Y, Li Y
    Evaluating Concordance and Clinical Utility of ctDNA Profiling in Advanced Biliary Tract Cancer.
    J Hepatol. 2024 Nov 15:S0168-8278(24)02715-6. doi: 10.1016/j.jhep.2024.
    >> Share

  79. LUO P, Lin A, Miao K
    Balancing strengths and limitations of ctDNA in advanced biliary tract cancer genomic profiling.
    J Hepatol. 2024 Nov 15:S0168-8278(24)02716-8. doi: 10.1016/j.jhep.2024.
    >> Share

  80. LIU Y, Wei Y, Chen X, Huang S, et al
    Genetic study of intrahepatic cholestasis of pregnancy in Chinese women unveils East Asian etiology linked to historic HBV epidemic.
    J Hepatol. 2024 Nov 13:S0168-8278(24)02708-9. doi: 10.1016/j.jhep.2024.
    >> Share

  81. HENGSTLER JG, Vartak N
    Activating hepatobiliary water channels for gallstone prevention in complicated gallstone disease.
    J Hepatol. 2024 Nov 12:S0168-8278(24)02704-1. doi: 10.1016/j.jhep.2024.
    >> Share

  82. YOO C, Jeong H, Jeong JH, Kim KP, et al
    Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma.
    J Hepatol. 2024 Nov 10:S0168-8278(24)02666-7. doi: 10.1016/j.jhep.2024.
    >> Share

    October 2024
  83. HWANG S, Woo S, Kang B, Kang H, et al
    Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer.
    J Hepatol. 2024 Oct 21:S0168-8278(24)02641-2. doi: 10.1016/j.jhep.2024.
    >> Share

  84. TALANIAN M, Almeqdadi M, Chen HH
    From dark bile to bright insight: A liver biopsy with advanced fibrosis and severe cholestasis.
    J Hepatol. 2024;81:e147-e150.
    >> Share

  85. YOUNOSSI ZM, Kremer AE, Swain MG, Jones D, et al
    Assessment of fatigue and its impact in chronic liver disease.
    J Hepatol. 2024;81:726-742.
    >> Share

    September 2024
  86. DIXON ED, Claudel T, Nardo AD, Riva A, et al
    Inhibition of ATGL alleviates MASH via impaired PPARalpha signalling that favours hydrophilic bile acid composition in mice.
    J Hepatol. 2024 Sep 30:S0168-8278(24)02577-7. doi: 10.1016/j.jhep.2024.
    >> Share

  87. FUCHS CD, Simbrunner B, Baumgartner M, Campell C, et al
    Bile acid metabolism and signaling in liver disease.
    J Hepatol. 2024 Sep 28:S0168-8278(24)02572-8. doi: 10.1016/j.jhep.2024.
    >> Share

  88. HUO X, Yu Z, Zhao F, Chen Y, et al
    Hepatocyte Aquaporin 8-mediated Water Transport Facilitates Bile Dilution and Prevents Gallstone Formation in Mice.
    J Hepatol. 2024 Sep 24:S0168-8278(24)02563-7. doi: 10.1016/j.jhep.2024.
    >> Share

  89. HENRY L, Younossi ZM
    Fatigue and Patient Reported Outcomes (PROs) in Primary Sclerosing Cholangitis.
    J Hepatol. 2024 Sep 17:S0168-8278(24)02547-9. doi: 10.1016/j.jhep.2024.
    >> Share

    August 2024
  90. RAVANBAKHSH N, Genyk Y, Cheng A, Vats D, et al
    Biliary Cirrhosis associated with WDR19-Related Ciliopathy in Siblings.
    J Hepatol. 2024 Aug 18:S0168-8278(24)02475-9. doi: 10.1016/j.jhep.2024.
    >> Share

    July 2024
  91. HUANG P, Wei G, Kirkpatrick JD, Lin Y, et al
    Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis.
    J Hepatol. 2024 Jul 30:S0168-8278(24)02423-1. doi: 10.1016/j.jhep.2024.
    >> Share

  92. JOHANNES H, Laura B, Bernd L, Anne T, et al
    Fatigue is a symptom of clinical importance in patients with Primary Sclerosing Cholangitis (SOMA.LIV).
    J Hepatol. 2024 Jul 29:S0168-8278(24)02421-8. doi: 10.1016/j.jhep.2024.
    >> Share

    June 2024
  93. ESSER H, Kilpatrick AM, Man TY, Aird R, et al
    Primary cilia as a targetable node between biliary injury, senescence and regeneration in liver transplantation.
    J Hepatol. 2024 Jun 13:S0168-8278(24)02302-X. doi: 10.1016/j.jhep.2024.
    >> Share

  94. WU XN, Wang MZ, Zhang N, Zhang W, et al
    Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
    J Hepatol. 2024;80:928-940.
    >> Share

    May 2024
  95. MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
    Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
    >> Share


  96. EASL Clinical Practice Guidelines on genetic cholestatic liver diseases.
    J Hepatol. 2024 May 29:S0168-8278(24)00274-5. doi: 10.1016/j.jhep.2024.
    >> Share

  97. REVIEJO M, Lozano E, Marin JJG
    Impact of alternative splicing on cholangiocarcinoma progression through metabolic rewiring-induced epigenetic events.
    J Hepatol. 2024 May 27:S0168-8278(24)00365-9. doi: 10.1016/j.jhep.2024.
    >> Share

  98. KRAUSE J, Schramm C
    Multi-omics characterization of healthy and PSC human liver - what we knew and what we have learned.
    J Hepatol. 2024;80:681-683.
    >> Share

  99. ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
    Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
    J Hepatol. 2024;80:730-743.
    >> Share

    April 2024
  100. YANG L, Niu K, Wang J, Shen W, et al
    Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00278-2. doi: 10.1016/j.jhep.2024.
    >> Share

    March 2024
  101. LEMAIGRE FP
    Planar cell polarity is crucial for proper morphogenesis of the bile ducts.
    J Hepatol. 2024 Mar 26:S0168-8278(24)00217-4. doi: 10.1016/j.jhep.2024.
    >> Share

  102. XU L, Zhang Y, Lin Z, Deng X, et al
    FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    J Hepatol. 2024 Mar 18:S0168-8278(24)00199-5. doi: 10.1016/j.jhep.2024.
    >> Share

  103. RAAB M, Christodoulou E, Krishnankutty R, Gradinaru A, et al
    Van Gogh-like 2 is essential for the architectural patterning of the mammalian biliary tree.
    J Hepatol. 2024 Mar 7:S0168-8278(24)00149-1. doi: 10.1016/j.jhep.2024.
    >> Share

  104. LIM YZ, Zhu M, Wang Y, Sharma T, et al
    Pkd1l1-deficiency drives biliary atresia through ciliary dysfunction in biliary epithelial cells.
    J Hepatol. 2024 Mar 7:S0168-8278(24)00151-X. doi: 10.1016/j.jhep.2024.
    >> Share

  105. TOMLINSON JL, Li B, Yang J, Loeuillard E, et al
    Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma.
    J Hepatol. 2024 Mar 6:S0168-8278(24)00127-2. doi: 10.1016/j.jhep.2024.
    >> Share

    February 2024
  106. YANG Y, Wang J, Wan J, Cheng Q, et al
    PTEN Deficiency Induces an Extrahepatic Cholangitis-Cholangiocarcinoma Continuum via Aurora kinase A in Mice.
    J Hepatol. 2024 Feb 28:S0168-8278(24)00138-7. doi: 10.1016/j.jhep.2024.
    >> Share

    January 2024
  107. FAN X, Yang F, Zhou L, Yang L, et al
    Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00097-7. doi: 10.1016/j.jhep.2024.
    >> Share

  108. TANG R, Li Y, Chen R, Ma X, et al
    Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
    J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
    >> Share

  109. NAYAGAM JS, Miquel R, Thompson RJ, Joshi D, et al
    Genetic cholestasis in children and adults.
    J Hepatol. 2024 Jan 30:S0168-8278(23)05305-9. doi: 10.1016/j.jhep.2023.
    >> Share

  110. TRAMPERT DC, Beuers U
    A beneficial response of fetal wound healing gone bad in the bile duct: The overarching cause of biliary atresia?
    J Hepatol. 2024 Jan 4:S0168-8278(23)05372-2. doi: 10.1016/j.jhep.2023.
    >> Share

  111. ZHENG C, Wang L, Zou T, Lian S, et al
    Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8+ T cells.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00004-7. doi: 10.1016/j.jhep.2023.
    >> Share

    November 2023
  112. KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
    ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
    J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
    >> Share

  113. FICKERT P
    Detour of bile acids routes as therapeutic roadmap for cholemic nephropathy.
    J Hepatol. 2023 Nov 25:S0168-8278(23)05283-2. doi: 10.1016/j.jhep.2023.
    >> Share

  114. DIPERI TP, Zhao M, Evans KW, Varadarajan K, et al
    Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    J Hepatol. 2023 Nov 14:S0168-8278(23)05274-1. doi: 10.1016/j.jhep.2023.
    >> Share

  115. VAN MUNSTER KN, Bergquist A, Ponsioen CY
    Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?
    J Hepatol. 2023 Nov 6:S0168-8278(23)05158-9. doi: 10.1016/j.jhep.2023.
    >> Share

  116. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
    Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
    >> Share

    October 2023
  117. DE JONG IEM, Theise ND, Wells RG
    The space of Mall confirmed in humans: a response to "Portal venous branches as an anatomic railroad for a gut-bile duct axis".
    J Hepatol. 2023 Oct 9:S0168-8278(23)05155-3. doi: 10.1016/j.jhep.2023.
    >> Share

  118. TRUSSONI CE, LaRusso NF
    Macrophages make a difference in cholestatic liver diseases - but how?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05149-8. doi: 10.1016/j.jhep.2023.
    >> Share

  119. MALAKAR S, Mishra P, Paturu R, Verma R, et al
    Primary sclerosing cholangitis with high immunoglobulin-G4.
    J Hepatol. 2023 Oct 7:S0168-8278(23)05153-X. doi: 10.1016/j.jhep.2023.
    >> Share

    September 2023

  120. Corrigendum to "EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma" [J Hepatol (79) (2023) 181-208].
    J Hepatol. 2023 Sep 23:S0168-8278(23)05092-4. doi: 10.1016/j.jhep.2023.
    >> Share


  121. Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].
    J Hepatol. 2023 Sep 19:S0168-8278(23)05091-2. doi: 10.1016/j.jhep.2023.
    >> Share

  122. ABERG F, Sallinen V, Tuominen S, Adam R, et al
    Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity-score matched intention-to-treat analysis.
    J Hepatol. 2023 Sep 16:S0168-8278(23)05100-0. doi: 10.1016/j.jhep.2023.
    >> Share

    August 2023
  123. CHEN R, Huang B, Lian M, Wei Y, et al
    A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
    J Hepatol. 2023 Aug 31:S0168-8278(23)05069-9. doi: 10.1016/j.jhep.2023.
    >> Share

  124. LIMOUSIN W, Laurent-Puig P, Ziol M, Ganne-Carrie N, et al
    Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
    J Hepatol. 2023 Aug 28:S0168-8278(23)05070-5. doi: 10.1016/j.jhep.2023.
    >> Share

  125. DE JONG IEM, Hunt ML, Chen D, Du Y, et al
    A fetal wound healing program after intrauterine bile duct injury may contribute to biliary atresia.
    J Hepatol. 2023 Aug 21:S0168-8278(23)05060-2. doi: 10.1016/j.jhep.2023.
    >> Share

  126. KERSTEN R, Trampert DC, Herta T, Hubers LM, et al
    IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies.
    J Hepatol. 2023 Aug 18:S0168-8278(23)05058-4. doi: 10.1016/j.jhep.2023.
    >> Share

  127. GLESSNER JT, Ningappa MB, Ngo KA, Zahid M, et al
    Biliary atresia is associated with polygenic susceptibility in ciliogenesis and planar polarity effector genes.
    J Hepatol. 2023 Aug 10:S0168-8278(23)05040-7. doi: 10.1016/j.jhep.2023.
    >> Share

  128. ROMA K, Mohammed S, Sieck B, Naik K, et al
    Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation.
    J Hepatol. 2023;79:581-584.
    >> Share

    July 2023
  129. DE MARTIN E, Laurent-Bellue A, Routier E, Samuel D, et al
    Acute cholestatic hepatitis in a patient with metastatic melanoma.
    J Hepatol. 2023;79:e13-e15.
    >> Share

  130. D'ARTISTA L, Moschopoulou AA, Barozzi I, Craig AJ, et al
    MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    J Hepatol. 2023;79:141-149.
    >> Share

    June 2023
  131. ROMEO M, Dallio M, Federico A
    Multidrug Resistance Protein 6 (ABCC6/MRP6) loss of function causing Pseudoxanthoma elasticum (PXE) is associated with Low-Phospholipid Associated Cholelithiasis (LPAC) features: is it time to reconsider the MRP6 role in bile secretion and LPAC geneti
    J Hepatol. 2023 Jun 29:S0168-8278(23)04936-X. doi: 10.1016/j.jhep.2023.
    >> Share

  132. ARINO S, Aguilar-Bravo B, Coll M, Lee WY, et al
    Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00423-3. doi: 10.1016/j.jhep.2023.
    >> Share

  133. ALMAAS R, Atneosen-Asegg M, Ytre-Arne ME, Melheim M, et al
    Aagenaes syndrome/lymphedema cholestasis syndrome 1 is caused by a founder variant in the 5'-untranslated region of UNC45A.
    J Hepatol. 2023 Jun 14:S0168-8278(23)00410-5. doi: 10.1016/j.jhep.2023.
    >> Share

  134. BRAADLAND PR, Bergquist A, Kummen M, Bossen L, et al
    Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
    J Hepatol. 2023 Jun 14:S0168-8278(23)00415-4. doi: 10.1016/j.jhep.2023.
    >> Share

  135. LATTANZI B, Covotta F, Cardinale V
    The Potential Role Of Endoscopy Ultrasound In Primary Sclerosing Cholangitis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00404-X. doi: 10.1016/j.jhep.2023.
    >> Share

    May 2023
  136. TOMLINSON JL, Valle JW, Ilyas SI
    Immunobiology of Cholangiocarcinoma.
    J Hepatol. 2023 May 16:S0168-8278(23)00338-0. doi: 10.1016/j.jhep.2023.
    >> Share

  137. BOLDUAN F, Geisel D, Pahl S, Wree A, et al
    Painless jaundice with segmental obstructive cholestasis.
    J Hepatol. 2023 May 9:S0168-8278(23)00209-X. doi: 10.1016/j.jhep.2023.
    >> Share

    April 2023
  138. GRADY J, Clifford C, Treadwell MC, Parikh ND, et al
    The Use of Fenofibrate for Intrahepatic Cholestasis of Pregnancy.
    J Hepatol. 2023 Apr 19:S0168-8278(23)00237-4. doi: 10.1016/j.jhep.2023.
    >> Share

  139. DANA J, Debray D, Vilgrain V
    Reply to: "The effects of CFTR modulator therapies on liver stiffness and bile flow: a single centre experience".
    J Hepatol. 2023 Apr 10:S0168-8278(23)00222-2. doi: 10.1016/j.jhep.2023.
    >> Share

  140. FICKERT P, Lin AC, Ritschl H, Hammer N, et al
    Portal venous branches as an anatomic railroad for a gut-bile duct-axis.
    J Hepatol. 2023 Apr 10:S0168-8278(23)00221-0. doi: 10.1016/j.jhep.2023.
    >> Share

    March 2023

  141. EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma.
    J Hepatol. 2023 Mar 22:S0168-8278(23)00185-X. doi: 10.1016/j.jhep.2023.
    >> Share

  142. RICCIUTO A, Kamath BM, Hirschfield GM, Trivedi PJ, et al
    Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?
    J Hepatol. 2023 Mar 2:S0168-8278(23)00162-9. doi: 10.1016/j.jhep.2023.
    >> Share

  143. LAPITZ A, Azkargorta M, Milkiewicz P, Olaizola P, et al
    Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma.
    J Hepatol. 2023 Mar 1:S0168-8278(23)00159-9. doi: 10.1016/j.jhep.2023.
    >> Share

    February 2023
  144. DUWE L, Munoz-Garrido P, Lewinska M, Lafuente-Barquero J, et al
    MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells.
    J Hepatol. 2023;78:364-375.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016